DXB 8.89% 49.0¢ dimerix limited

Ann: Quarterly Appendix 4C and Activities Report, page-19

  1. 6,434 Posts.
    lightbulb Created with Sketch. 5274
    Hi BTB,

    In the initial ANN for REMAP-CAP last June, Dimerix had filed provisional patent applications in all key jurisdictions for DMX-200 & ARDS, so whether India was included then, not sure, but I’m guessing it would be (at least now). As we know they are big on patents.

    I hope Nina is able to answer your questions BTB. Just a thought, but even if DXB are not informed of progress on REMAP-CAP, being responsible for drug supply from the GMP Manufacturer in the USA, you would think trial sites coming on board & triggering the supply chain, that would give some indication that things are progressing at least. I think the plan was to run the Ph2 from a couple of sites, & if successful, expand to other sites on progression to Ph3.

    GLTAH

 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.